The NEO-MINDSET trial demonstrated that among patients with acute coronary syndrome (ACS) who underwent successful percutaneous coronary intervention (PCI), early discontinuation of aspirin and continuation with potent P2Y12 inhibitor monotherapy failed to demonstrate non-inferiority to dual antiplatelet therapy (DAPT) in terms of the 12-month composite ischemic endpoint of all-cause death, myocardial infarction (MI), stroke, or urgent target vessel revascularization (TVR), according to a study presented by Dr. Pedro A. Lemos, Hospital Israelita Albert Einstein, Brazil, in the Hot Line session at ESC Congress 2025.